619 related articles for article (PubMed ID: 29454904)
21. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
22. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Doyle C; Das SC
Int J Pharm; 2017 Aug; 528(1-2):107-117. PubMed ID: 28583333
[TBL] [Abstract][Full Text] [Related]
23. Amino acids as stabilizers for spray-dried simvastatin powder for inhalation.
Lu W; Rades T; Rantanen J; Chan HK; Yang M
Int J Pharm; 2019 Dec; 572():118724. PubMed ID: 31678523
[TBL] [Abstract][Full Text] [Related]
24. Stabilization of IgG1 in spray-dried powders for inhalation.
Schüle S; Schulz-Fademrecht T; Garidel P; Bechtold-Peters K; Frieb W
Eur J Pharm Biopharm; 2008 Aug; 69(3):793-807. PubMed ID: 18477504
[TBL] [Abstract][Full Text] [Related]
25. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
26. Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders.
Chew NY; Bagster DF; Chan HK
Int J Pharm; 2000 Sep; 206(1-2):75-83. PubMed ID: 11058812
[TBL] [Abstract][Full Text] [Related]
27. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
28. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
Li X; Vogt FG; Hayes D; Mansour HM
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
[TBL] [Abstract][Full Text] [Related]
29. Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients.
Minne A; Boireau H; Horta MJ; Vanbever R
Eur J Pharm Biopharm; 2008 Nov; 70(3):839-44. PubMed ID: 18620052
[TBL] [Abstract][Full Text] [Related]
30. Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.
Alhajj N; O'Reilly NJ; Cathcart H
Int J Pharm; 2022 Apr; 618():121657. PubMed ID: 35288220
[TBL] [Abstract][Full Text] [Related]
31. Aerosolization properties, surface composition and physical state of spray-dried protein powders.
Bosquillon C; Rouxhet PG; Ahimou F; Simon D; Culot C; Préat V; Vanbever R
J Control Release; 2004 Oct; 99(3):357-67. PubMed ID: 15451594
[TBL] [Abstract][Full Text] [Related]
32. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
Eedara BB; Rangnekar B; Doyle C; Cavallaro A; Das SC
Int J Pharm; 2018 May; 542(1-2):72-81. PubMed ID: 29524618
[TBL] [Abstract][Full Text] [Related]
33. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
34. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
Momin MAM; Sinha S; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
[TBL] [Abstract][Full Text] [Related]
35. Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.
Shetty N; Zhang Y; Park H; Zemlyanov D; Shah D; He A; Ahn P; Mutukuri TT; Chan HK; Zhou QT
Pharm Res; 2020 Oct; 37(11):219. PubMed ID: 33037471
[TBL] [Abstract][Full Text] [Related]
36. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders.
Maa YF; Nguyen PA; Andya JD; Dasovich N; Sweeney TD; Shire SJ; Hsu CC
Pharm Res; 1998 May; 15(5):768-75. PubMed ID: 9619788
[TBL] [Abstract][Full Text] [Related]
37. Characterization of excipient enhanced growth (EEG) tobramycin dry powder aerosol formulations.
Hassan A; Farkas D; Longest W; Hindle M
Int J Pharm; 2020 Dec; 591():120027. PubMed ID: 33130220
[TBL] [Abstract][Full Text] [Related]
38. Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs.
Ke WR; Chang RYK; Kwok PCL; Chen D; Chan HK
Int J Pharm; 2020 Dec; 591():119984. PubMed ID: 33069893
[TBL] [Abstract][Full Text] [Related]
39. The use of sodium carboxymethylcellulose in the preparation of spray-dried proteins for pulmonary drug delivery.
Li HY; Song X; Seville PC
Eur J Pharm Sci; 2010 Apr; 40(1):56-61. PubMed ID: 20188824
[TBL] [Abstract][Full Text] [Related]
40. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
Kaewjan K; Srichana T
Pharm Dev Technol; 2016; 21(1):68-75. PubMed ID: 25331092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
